Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30519105 | 1.00 | UCHL1 (0.60) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL29739756 | 0.89 | UCHL1 (0.58) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL17021263 | 0.89 | UCHL1 (0.58) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL15271994 | 0.85 | SCN9A (0.52) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL17021259 | 0.85 | SCN9A (0.51) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL29739758 | 0.85 | SCN9A (0.51) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL15272482 | 0.85 | SCN9A (0.52) | UCHL1ABHD6SCN9ASCN5AESR2 | |
| SCHEMBL31742231 | 0.84 | ABHD6 (0.48) | UCHL1ABHD6SCN9ASCN5ANAMPT | |
| SCHEMBL31742172 | 0.84 | ABHD6 (0.48) | UCHL1ABHD6SCN9ASCN5ANAMPT | |
| SCHEMBL28107776 | 0.84 | SCN9A (0.59) | UCHL1ABHD6SCN9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376445-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-11 | — | — | US | disclosed |
| EP-4654970-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-04-24 | — | — | US | disclosed |
| WO-2024210578-A1 | HETEROBICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 바오밥에이바이오 | 2024-10-10 | — | — | WO | disclosed |
| WO-2024159079-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023147063-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-11401258-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| US-10738026-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738026-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| EP-3105217-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123398-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123398-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738026-B2 | Isoquinoline derivatives and use thereof | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885SCN9A 67/4885 |
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | UCHL1 4050/4885ABHD6 3095/4885SCN9A 1683/4885 |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885SCN9A 67/4885 |
| US-20250376445-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | UCHL1 3977/4885ABHD6 3509/4885SCN9A 1071/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885SCN9A 67/4885 |
| US-11401258-B2 | Isoquinoline derivatives and use thereof | KCNQ3, KCNQ5, KCNQ4 | UCHL1 3538/4885ABHD6 3395/4885SCN9A 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.